Research programme: breast cancer gene therapy - Copernicus Therapeutics

Drug Profile

Research programme: breast cancer gene therapy - Copernicus Therapeutics

Latest Information Update: 25 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Copernicus Therapeutics
  • Developer Case Western Reserve University; National Cancer Institute (USA)
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 25 Mar 2008 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
  • 07 Dec 2006 Preclinical development is still ongoing
  • 01 Aug 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top